Genentech revealed favorable topline results from the Phase III CENTERSTONE trial of Xofluza® (baloxavir marboxil).

Satellos Bioscience announced that the initial participant has received a dose in a Phase 1 clinical trial of SAT-3247.

Fasenra granted approval in the United States for treatment of eosinophilic granulomatosis with polyangiitis.

Givastomig is a pioneering first-in-class bispecific antibody immunostimulant targeting Claudin18.2 (CLDN18.2) and 4-1BB.

The FDA has greenlighted Novartis' Kisqali® to lower the chance of recurrence in patients with early-stage HR+/HER2- breast cancer.

Innovent Presents Clinical Results of IBI363 (Novel PD-1/IL-2α-bispecific Antibody) with Bevacizumab in Advanced Colorectal Cancer at 2024 ESMO Congress.

Senhwa Biosciences submits IND to FDA for NCI-sponsored Pidnarulex pharmacodynamics pilot study in advanced solid tumor patients.

Patritumab Deruxtecan showed a notable enhancement in progression-free survival compared to doublet chemotherapy in patients with advanced or metastatic EGFR-mutated NSCLC.

AC Immune Gets Another Payment After Advancing Phase 2b ReTain Trial for ACI-35.030 in Early Alzheimer’s.

NextCure has disclosed that clinical findings from the Phase 1b segment of a Phase 1b/2 trial assessing NC410, a LAIR-2 fusion protein.

Trishula Therapeutics Shows Promising Phase 1 Results for TTX-030 in Initial Treatment of Metastatic Pancreatic Cancer.

ImmVira Presents Clinical Data on Intravesical MVR-T3011 for High-Risk BCG-Failure NMIBC at ESMO 2024.